Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer.
Ravi K GoyalJingchuan ZhangKeith L DavisMartina Sluga-O'CallaghanPeter A KaufmanPublished in: Breast cancer research and treatment (2024)
Our real-world study suggests that eribulin may be a potential treatment option for MBC patients who fail a prior PI3K inhibitor.